Both breast cancer mutants led to an increased tyrosine phosphorylation of FRS2, a well-characterized FGFR2 substrate, as revealed by immunoblotting with anti-p-FRS2 antibody after SDS-PAGE. Here, FGFR2 is linked to breast cancer.